To the Editor: Hyperbilirubinemia with severe liver metastases is a fatal complication of metastatic colorectal cancer. According to the recent report from Mayo clinic, the median survival times of .1 month with supportive care alone and 71 days in patients treated with first-line chemotherapy with fluoropyrimidine and oxaliplatin (1) . Cetuximab has been shown to improve the prognosis of pre-treated advanced colorectal cancer significantly compared with best supportive care alone (2) . However, since the eligibility criteria of most clinical trials exclude patients with hyperbilirubinemia, the feasibility or efficacy of cetuximab for patients with hyperbilirubinemia is unknown. To address this issue, we evaluated the efficacy and safety of cetuximab retrospectively in seven consecutive patients (Table 1) with metastatic colorectal cancer with hyperbilirubinemia (.2.0 mg/dl) due to multiple liver metastases. ECOG performance status was 1 in one patient, 2 in four patients and 3 in two patients. All patients had received prior irinotecan, and six patients received prior fluoropyrimidine and oxaliplatin and then progressed. Prior biliary drainage was performed in two patients, and the other five patients could not undergo drainage due to a diffuse disease type. The median serum total bilirubin concentration was 7.0 mg/dl (range 2.3-13.0 mg/dl). KRAS status was evaluated in all seven patients and was wild type in six patients. Although one patient was determined to have a KRAS-mutated tumor, this patient initiated cetuximab before the report of KRAS status was available, because of rapid disease progression. All patients were treated with the approved dosage and schedule of cetuximab: initially 400 mg/m 2 followed by weekly infusions of 250 mg/m 2 . Although no clear mechanism detailing the metabolism of cetuximab has been reported, monoclonal antibodies like cetuximab are thought to be metabolized by the reticuloendothelial system without undergoing hepatic or renal metabolism (3, 4) . Therefore, we planned to use cetuximab without dose reduction. The median number of cetuximab administrations was 4 (range 2 -14). Two patients Jpn
(28.5%) experienced apparent improvement of total bilirubin (from 2.6 to 0.8 mg/dl and from 7.9 to 3.0 mg/dl). One patient showed apparent radiological tumor shrinkage ( Fig. 1) (5) . The other patient with decreased bilirubin showed minor tumor response. The median survival time was 2.5 months (range 0.5 -5.8 months). Although Grade 2 skin toxicity was observed in three patients, no other unexpected severe toxicities and no treatment-related deaths were observed. Therefore, cetuximab monotherapy without dose modification may be feasible in patients with hyperbilirubinemia due to severe liver metastases. The efficacy of cetuximab monotherapy was modest in our cohort, despite the fact that most patients had KRAS wild-type tumors, although our survival time was similar to that in the first-line setting (1) . Further effective treatment might be necessary to improve the prognosis. 276 Letter
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